Business
CTT Pharmaceutical Holdings, Inc., (CTTH) Announces National Patent Applications Worldwide for Orally Administrable Nanonized Opioids, Cannabinoids, Nutraceuticals and Other Pharmaceutical Agents
CTT Pharmaceutical Holdings, Inc., (CTTH) Announces National Patent Applications Worldwide for Orally Administrable Nanonized Opioids, Cannabinoids, Nutraceuticals and Other Pharmaceutical Agents.
About this update from Ctt Pharmaceutical Holdings, Inc.
[{"type":"text","content":"\nIncludes All Markets in which Aurora Cannabis Currently Operates or Contemplates Future Operations \n Hamilton, Ontario, Jan. 15, 2019 (GLOBE NEWSWIRE) -- CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC:CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, is pleased to announce that it has filed national patent applications that encompass over 50 countries for its titled “Orally Administrable Composition” technology.  This patent application broadly covers products such as Oral Thin Films, Wafers, Strips, Tablets, Gums etc. that deliver active nanonized pharmaceuticals including cannabinoids, opioids and most other large therapeutic molecules. CTT filed an International Patent Application under the Patent Cooperation Treaty (“PCT”) on February 27, 2017 for an orally administrable composition comprising a nanonized therapeutic such as an opioid, cannabinoid and nutraceutical.  The application was published under the PCT on September 8, 2017 as WO 2017/147691.  Based on CTT’s International Patent Application under the PCT, CTT has moved into the “national phase” with applications in various countries around the world including in Europe, Australia, the Middle East, Africa, the Caribbean, and South America.   “The initial patentability opinion received from the PCT office was positive, underscoring the novel nature of our technology and affirming our outlook to obtain patent acceptance in other countries in due course,” said Cam Birge, CEO of CTT Pharmaceutical. “This opinion is further supported by the issuance of a patent to CTT in Canada for our innovative oral thin film wafer technology, a fast dissolving, dose specific, smoke-free delivery of cannabis for the medical and Canadian Adult-use markets. Our oral thin film wafer is made from FDA approved non-medical ingredients used in several pharmaceutical formulations resulting in rapid onset of action within 5 minutes after dosing.” About CTT Pharmaceutical CTT’s patent portfolio currently contains five issued (three Canadian and two U.S.) patents with a number of national patent applications pending that encompass over fifty countries.  Aurora Cannabis (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) currently has an app...